Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
•
Breast Cancer, Non-metastatic
Is there evidence supporting the adjuvant use of neratinib in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer that harbors an activating HER2 mutation?
Related Questions
What are your top takeaways in Breast Cancer from ASTRO 2024?
Would you give adjuvant TDM-1 to a patient with HER2-positive breast cancer s/p NAC with TCHP found to have no residual disease in the breast, but presence of ITCs ypN0(i+) in one axillary lymph node?
What are your top takeaways in Medical Oncology from SABCS 2024?
What are your top takeaways in Breast Cancer from ESMO 2024?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
In light of WSG-ADAPT HR+/HER2– trial at SABCS 2024 showing a 5 year iDFS benefit with neoadjuvant nab-paclitaxel over paclitaxel, will you change your practice?
Is there safety data regarding the use of hormonal IUDs in patients with atypical ductal hyperplasia and other high risk, non-malignant breast lesions?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
